Sun Pharmaceutical Industries has initiated a postal ballot seeking shareholder approval to increase its borrowing and investment limits up to INR 800 billion. These funds are designated to support the USD 12 billion acquisition of Organon & Co. Additionally, the company is proposing a new ESOP 2026 plan involving 12 million options, which will be sourced via the secondary market to ensure zero equity dilution for existing shareholders.
Sun Pharma Seeks Shareholder Approval for Organon Acquisition and New ESOP
Investment Limit: INR 800 Billion | Borrowing Limit: INR 700 Billion
Reader Takeaway: Strategic acquisition headroom increases without equity dilution, though debt levels will rise upon deal execution.
What just happened
Sun Pharmaceutical Industries Limited has launched a postal ballot to secure shareholder approval for seven special resolutions. These resolutions primarily focus on expanding the company's financial flexibility to facilitate the acquisition of Organon & Co. The company is also seeking approval for the 'Sun Pharma Employees Stock Option Plan 2026' (ESOP 2026).
Why this matters
The proposed acquisition of Organon & Co. is a significant strategic move for Sun Pharma, requiring approximately USD 12 billion in financing. To enable this, the company needs to enhance its authorized limits under Sections 186 and 180 of the Companies Act. Specifically, Sun Pharma is seeking to raise its investment/loan limit to INR 800 billion and its borrowing limit to INR 700 billion. The company is also securing permission to create security interests over assets up to INR 700 billion.
ESOP 2026 Structure
Sun Pharma has structured the new ESOP 2026 to be shareholder-friendly by opting for secondary market acquisition. The plan, which covers 12 million options for eligible employees across the group, will be managed via an employee welfare trust. Crucially, the company has confirmed there will be no fresh issuance of shares, ensuring no dilution of equity for existing investors.
Voting Process
Shareholders eligible as of the cut-off date of September 25, 2026, can participate in the e-voting process. The window is open from October 2, 2026, to October 31, 2026. The final results are expected to be announced on or before November 3, 2026.
Risks to watch
While these are enabling resolutions, the significant increase in debt-servicing requirements following the Organon acquisition remains a key factor. Investors should monitor how the company manages its balance sheet post-acquisition and the specific terms of the debt instruments utilized.
What to track next
Watch for official disclosures regarding the finalization of the Organon acquisition financing and the actual utilization of the newly approved limits.